within Pharmacolibrary.Drugs.ATC.N;

model N06DX01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 1.0,
    Cl             = 0.00022666666666666666,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.43,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005783333333333334,
    Tlag           = 600,            
    Vdp             = 0.119,
    k12             = 26.3,
    k21             = 26.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06DX01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Memantine is a moderate-affinity, uncompetitive NMDA receptor antagonist used primarily in the management of moderate to severe Alzheimer's disease. Memantine is approved and widely used for symptomatic treatment to slow cognitive decline in neurodegenerative conditions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported from healthy adult volunteers after a single oral administration.</p><h4>References</h4><ol><li><p>Lee, SH, et al., &amp; Bae, CS (2016). Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats. <i>Basic &amp; clinical pharmacology &amp; toxicology</i> 118(2) 122–127. DOI:<a href=\"https://doi.org/10.1111/bcpt.12479\">10.1111/bcpt.12479</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26310825/\">https://pubmed.ncbi.nlm.nih.gov/26310825</a></p></li><li><p>DeBattista, C, &amp; Schatzberg, AF (2024). The Black Book of Psychotropic Dosing and Monitoring. <i>Psychopharmacology bulletin</i> 54(3) 8–59. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38993656/\">https://pubmed.ncbi.nlm.nih.gov/38993656</a></p></li><li><p>Kanasty, R, et al., &amp; Bellinger, AM (2019). A pharmaceutical answer to nonadherence: Once weekly oral memantine for Alzheimer&#x27;s disease. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 303 34–41. DOI:<a href=\"https://doi.org/10.1016/j.jconrel.2019.03.022\">10.1016/j.jconrel.2019.03.022</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30928488/\">https://pubmed.ncbi.nlm.nih.gov/30928488</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06DX01;
